Is a new biotech company based in the Greater Boston area focused on innovation for impaired executive functioning in people with ADHD and other neurological disorders.

We develop AKA1315, a novel non-stimulant small molecule drug initially focused on ADHD.

Our seasoned founding team has started six biotech companies and brought five drugs to market.